<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: This article provides recommendations on the use of antithrombotic therapy in patients with <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We generated treatment recommendations (Grade 1) and suggestions (Grade 2) based on high (A), moderate (B), and low (C) quality evidence </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, we recommend IV recombinant tissue plasminogen activator (r-tPA) if treatment can be initiated within 3 h (Grade 1A) or 4.5 h (Grade 2C) of symptom <z:hpo ids='HP_0003674'>onset</z:hpo>; we suggest intraarterial r-tPA in patients ineligible for IV tPA if treatment can be initiated within 6 h (Grade 2C); we suggest against the use of mechanical thrombectomy (Grade 2C) although carefully selected patients may choose this intervention; and we recommend early aspirin therapy at a dose of 160 to 325 mg (Grade 1A) </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> and restricted mobility, we suggest the use of prophylactic-dose <z:chebi fb="5" ids="28304">heparin</z:chebi> or intermittent pneumatic compression devices (Grade 2B) and suggest against the use of elastic compression stockings (Grade 2B) </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with a history of noncardioembolic <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0002326'>TIA</z:hpo>, we recommend long-term treatment with aspirin (75-100 mg once daily), <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (75 mg once daily), aspirin/extended release <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (25 mg/200 mg bid), or cilostazol (100 mg bid) over no antiplatelet therapy (Grade 1A), oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (Grade 1B), the combination of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> plus aspirin (Grade 1B), or triflusal (Grade 2B) </plain></SENT>
<SENT sid="5" pm="."><plain>Of the recommended antiplatelet regimens, we suggest <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> or aspirin/extended-release <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> over aspirin (Grade 2B) or cilostazol (Grade 2C) </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with a history of <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>TIA</z:hpo> and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> we recommend oral anticoagulation over no antithrombotic therapy, aspirin, and combination therapy with aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (Grade 1B) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These recommendations can help clinicians make evidence-based treatment decisions with their patients who have had <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
</text></document>